Cargando…

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells

XPO1/CRM1 is a key nuclear exporter protein that mediates translocation of numerous cellular regulatory proteins. We investigated whether XPO1 is a potential therapeutic target in melanoma using novel selective inhibitors of nuclear export (SINE). In vitro effects of SINE on cell growth and apoptosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jennifer, Bill, Matthew A., Young, Gregory S., La Perle, Krista, Landesman, Yosef, Shacham, Sharon, Kauffman, Michael, Senapedis, William, Kashyap, Trinayan, Saint-Martin, Jean-Richard, Kendra, Kari, Lesinski, Gregory B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109950/ https://www.ncbi.nlm.nih.gov/pubmed/25057921 http://dx.doi.org/10.1371/journal.pone.0102983

Ejemplares similares

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity
por: Saulino, David M., et al.
Publicado: (2018)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
por: Walker, Christopher J., et al.
Publicado: (2022)

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
por: Liu, Xuejiao, et al.
Publicado: (2016)

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
por: Pan, Lijia, et al.
Publicado: (2021)

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth
por: Wettersten, Hiromi I., et al.
Publicado: (2014)

Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
por: von Fallois, Moritz, et al.
Publicado: (2021)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
por: Yoshimura, Mariko, et al.
Publicado: (2014)

IFI27/ISG12 Downregulates Estrogen Receptor α Transactivation by Facilitating Its Interaction With CRM1/XPO1 in Breast Cancer Cells
por: Cervantes-Badillo, Mayte Guadalupe, et al.
Publicado: (2020)

Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3
por: Soung, Young Hwa, et al.
Publicado: (2017)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization
por: Wrobel, Kinga, et al.
Publicado: (2016)

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
por: Fisher, Jack G., et al.
Publicado: (2023)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
por: Khan, Husain Yar, et al.
Publicado: (2019)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
por: Turner, Joel G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i16lg1uocreg5ilp81kbp55k3f